RHODES JASON P sold 16.4% of their position (227.34K shares) of DYNE THERAPEUTICS, INC. on the open market
Open‑market sale worth $4.18M — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Stock
Shares
−59.87K
Price / share
$18.38
Trade value
$1.10M
% of position
Common Stock
Shares
−119.11K
Price / share
$18.38
Trade value
$2.19M
% of position
Common Stock
Shares
−1.17K
Price / share
$18.38
Trade value
$21.50K
% of position
Common Stock
Shares
−47.08K
Price / share
$18.38
Trade value
$865.37K
% of position
Common Stock
Shares
−26.00
Price / share
$19.00
Trade value
$494.00
% of position
Common Stock
Shares
−52.00
Price / share
$19.00
Trade value
$988.00
% of position
Common Stock
Shares
−1.00
Price / share
$19.00
Trade value
$19.00
% of position
Common Stock
Shares
−21.00
Price / share
$19.00
Trade value
$399.00
% of position
Net shares
−227.34K
Net value
-$4.18M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 4/28/2026 | S · Sale | −59.87K | $18.38 | $1.10M | 3.7% | 1.64M | 1.58M |
| Common Stock Indirect | 4/28/2026 | S · Sale | −119.11K | $18.38 | $2.19M | 2.4% | 5.06M | 4.94M |
| Common Stock Indirect | 4/28/2026 | S · Sale | −1.17K | $18.38 | $21.50K | 12.1% | 9.68K | 8.51K |
| Common Stock Indirect | 4/28/2026 | S · Sale | −47.08K | $18.38 | $865.37K | 3.9% | 1.21M | 1.16M |
| Common Stock Indirect | 4/28/2026 | S · Sale | −26.00 | $19.00 | $494.00 | 0.0% | 1.58M | 1.58M |
| Common Stock Indirect | 4/28/2026 | S · Sale | −52.00 | $19.00 | $988.00 | 0.0% | 4.94M | 4.94M |
| Common Stock Indirect | 4/28/2026 | S · Sale | −1.00 | $19.00 | $19.00 | 0.0% | 8.51K | 8.51K |
| Common Stock Indirect | 4/28/2026 | S · Sale | −21.00 | $19.00 | $399.00 | 0.0% | 1.16M | 1.16M |
| Total | −227.34K | -$4.18M | ||||||